Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | Director | June 09, 2020 | June 12, 2020 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | June 16, 2023 | June 21, 2023 |
| Guardant Health, Inc.GH · Entity 3238 | Director | September 16, 2026 | September 17, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date June 09, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2030-06-09 | Direct | 15,000 |
Reported balance
After 2020-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-09 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,202 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 38,202 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 781,797 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 781,797 F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Gritstone bio, Inc.
Report date June 16, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2033-06-15 | Direct | 51,800 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 51,800 · Balance 51,800 F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.
Guardant Health, Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,906 |
Ending reported balance
After 2026-09-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 1,103 · Balance 13,477 F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2026-09-16 · Sale · Disposed 3,300 · Balance 10,177 F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-09-16 · Sale · Disposed 1,300 · Balance 8,877 F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-09-16 · Sale · Disposed 971 · Balance 7,906 F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2023 Filed Nov 2, 2023 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000181 · wk-form4_1698883625.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2023 Filed Oct 2, 2023 21:14 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000163 · wk-form4_1696281241.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,091 Underlying: COMMON STOCK · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 30, 2023 Filed Oct 2, 2023 21:14 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000163 · wk-form4_1696281241.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000135 · wk-form4_1693946807.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,246 Underlying: COMMON STOCK · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000135 · wk-form4_1693946807.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:31 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,419 | $22.60 | $32,069.40 |
DisclosureSEC source: 0001714899-23-000132 · wk-form4_1692822662.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,799 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.51 to $22.99 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 31,502 RSUs. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000113 · wk-form4_1690927699.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,400 Underlying: COMMON STOCK · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000113 · wk-form4_1690927699.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 1,851 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000107 · wk-form4_1688590740.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,554 Underlying: COMMON STOCK · 1,851 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000107 · wk-form4_1688590740.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:48 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 51,800 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0000899243-23-016154 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,800 Underlying: Common Stock · 51,800 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:10 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRESTRICTED STOCK UNITS · Derivative | 5,592 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000099 · wk-form4_1686953399.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,592 Underlying: COMMON STOCK · 5,592 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:10 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 8,803 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0001576280-23-000099 · wk-form4_1686953399.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,803 Underlying: COMMON STOCK · 8,803 shares Expires 2033-06-14 F1 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 12,649 | $0.00 Strike: $30.92 | $0.00 |
DisclosureSEC source: 0001714899-23-000100 · wk-form4_1686002853.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,649 Underlying: Common Stock · 12,649 shares Expires 2033-06-01 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-23-000100 · wk-form4_1686002853.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,218 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 36,502 unvested RSUs. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,119 | $30.10 | $63,781.90 |
DisclosureSEC source: 0001714899-23-000031 · wf-form4_167650571634751.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,002 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.90 to $30.22 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 32,286 RSUs. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,377 | $30.88 | $42,521.76 |
DisclosureSEC source: 0001714899-23-000019 · wf-form4_167607058932396.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,121 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.76 to $31.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 39,572 restricted stock units. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 02:42 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,970 | $28.44 | $84,466.80 |
DisclosureSEC source: 0001714899-23-000015 · wf-form4_167331855351574.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,498 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 43,822 restricted stock units. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:47 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,253 | $33.22 | $74,844.66 |
DisclosureSEC source: 0001714899-22-000128 · wf-form4_166128765076444.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,468 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.11 to $33.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 51,322 restricted stock units. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:12 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 11,879 | $0.00 Strike: $48.96 | $0.00 |
DisclosureSEC source: 0001576280-22-000062 · wf-form4_166024871292786.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,879 Underlying: COMMON STOCK · 11,879 shares Expires 2032-08-09 F3 · derivative.exercise_date: The stock option vest as to 25% of the shares subject to such award on August 9, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on eachmonthly anniversary of August 9, 2023, during the three-year period thereafter. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:12 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRESTRICTED STOCK UNITS · Derivative | 7,405 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000062 · wf-form4_166024871292786.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,405 Underlying: COMMON STOCK · 7,405 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on August 9, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of August 9, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 23:36 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-22-000107 · wf-form4_165844658516817.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires 2022-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 23:36 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 62,500 | $0.68 | $42,500.00 |
DisclosureSEC source: 0001714899-22-000107 · wf-form4_165844658516817.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 56,322 restricted stock units. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:34 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001567619-22-013259 · doc1.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 23:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,560 | $34.69 | $88,806.40 |
DisclosureSEC source: 0001714899-22-000041 · wf-form4_164496940391476.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,221 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $34.50 to $35.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 87,322 restricted stock units. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,296 | $37.09 | $48,072.66 |
DisclosureSEC source: 0001714899-22-000036 · wf-form4_164461802552345.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,781 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $36.75 to $37.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 94608 restricted stock units. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 23:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,225 | $44.75 | $99,568.75 |
DisclosureSEC source: 0001714899-22-000007 · wf-form4_164159675294746.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,077 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.47 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 98,858 restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $47.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000001 · wf-form4_164142736337791.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2032-01-02 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2023, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000001 · wf-form4_164142736337791.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,302 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2023 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 106,358 restricted stock units. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:24 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 200 | $50.07 | $10,014.00 |
DisclosureSEC source: 0001714899-21-000084 · wf-form4_162976465052657.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,302 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.04 to $50.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 75,358 restricted stock units. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:24 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,085 | $49.52 | $103,249.20 |
DisclosureSEC source: 0001714899-21-000084 · wf-form4_162976465052657.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,502 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.00 to $49.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 75,358 restricted stock units. Read SEC document |
| June 18, 2021 Filed Nov 19, 2021 22:25 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0001567619-21-020868 · doc1.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,158 | $63.67 | $73,729.86 |
DisclosureSEC source: 0001209191-21-021122 · doc4.xml · nonDerivative · entry 4 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 850,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.67 to $63.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,258 | $62.71 | $204,318.95 |
DisclosureSEC source: 0001209191-21-021122 · doc4.xml · nonDerivative · entry 3 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 851,158 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.52 to $63.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 32,326 | $62.04 | $2,005,602.02 |
DisclosureSEC source: 0001209191-21-021122 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 854,416 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.52 to $62.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 13,258 | $61.16 | $810,912.31 |
DisclosureSEC source: 0001209191-21-021122 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 886,742 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.52 to $61.515 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:12 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 501 | $66.80 | $33,468.30 |
DisclosureSEC source: 0001209191-21-012052 · doc4.xml · nonDerivative · entry 4 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 900,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.66 to $67.075 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:12 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 16,616 | $66.20 | $1,099,995.82 |
DisclosureSEC source: 0001209191-21-012052 · doc4.xml · nonDerivative · entry 3 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 900,501 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.64 to $66.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:12 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,199 | $65.04 | $663,322.56 |
DisclosureSEC source: 0001209191-21-012052 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 917,117 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.63 to $65.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:12 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 22,684 | $64.27 | $1,457,923.36 |
DisclosureSEC source: 0001209191-21-012052 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 927,316 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.63 to $64.625 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:42 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $71.43 | $28,571.20 |
DisclosureSEC source: 0001209191-21-011006 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,587 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.06 to $71.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 80,358 previously reported restricted stock units and 7,285 shares acquired pursuant to vesting of restricted stock units. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:42 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,635 | $70.17 | $184,908.49 |
DisclosureSEC source: 0001209191-21-011006 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,987 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.675 to $70.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 80,358 previously reported restricted stock units and 7,285 shares acquired pursuant to vesting of restricted stock units. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 426 | $75.39 | $32,116.14 |
DisclosureSEC source: 0001209191-21-009890 · doc4.xml · nonDerivative · entry 3 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,979 F2 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.09 to $76.075 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,022 | $74.38 | $76,018.40 |
DisclosureSEC source: 0001209191-21-009890 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,405 F2 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.91 to $74.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2021 Filed Feb 12, 2021 00:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009890 · doc4.xml · derivative · entry 5 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F6 · derivative.exercise_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F6 · derivative.expiration_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2021 Filed Feb 12, 2021 00:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009890 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:46 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 14,147 | $73.01 | $1,032,815.88 |
DisclosureSEC source: 0001209191-21-004504 · doc4.xml · nonDerivative · entry 4 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 950,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $72.565 to $73.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:46 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,071 | $71.99 | $581,047.43 |
DisclosureSEC source: 0001209191-21-004504 · doc4.xml · nonDerivative · entry 3 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 964,147 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.56 to $72.555 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:46 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 12,981 | $70.96 | $921,157.72 |
DisclosureSEC source: 0001209191-21-004504 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 972,218 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.47 to $71.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:46 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 14,801 | $70.10 | $1,037,535.30 |
DisclosureSEC source: 0001209191-21-004504 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 985,199 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.445 to $70.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.